National Institute for Health Research Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, United Kingdom.
Radcliffe Department of Medicine, University of Oxford, Oxford, Oxford, United Kingdom.
Health Res Policy Syst. 2022 Feb 19;20(1):24. doi: 10.1186/s12961-022-00827-0.
With over 5 million COVID-19 deaths at the time of writing, the response of research leaders was and is critical to developing treatments to control the global pandemic. As clinical research leaders urgently repurposed existing research programmes and resources towards the COVID-19 pandemic, there is an opportunity to reflect on practices observed in Biomedical Research Centre (BRC) settings. BRCs are partnerships between leading National Health Service organizations and universities in England conducting translational research for patient benefit funded by the National Institute for Health Research (NIHR). Oxford BRC-supported researchers have led the rapid set-up of numerous COVID-19 research studies at record speed with global impact. However, the specific contribution of BRCs to the COVID-19 pandemic in the literature is sparse. Firstly, we reflect on the strategic work of clinical research leaders, creating resilient NIHR research infrastructure to facilitate rapid COVID-19 research. Secondly, we discuss how COVID-19 rapid research exemplars supported by Oxford BRC illustrate "capacity", "readiness" and "capability" at an organizational and individual level to respond to the global pandemic. Rapid response research in turbulent environments requires strategic organizational leadership to create resilient infrastructure and resources. The rapid research exemplars from the Oxford BRC illustrate capability and capacity at an organizational and individual level in a dynamic environment to respond during the COVID-19 public health challenge. This response was underpinned by swift adaptation and repurposing of existing research resources and expertise by the Oxford BRC to deliver rapid research to address different aspects of COVID-19.
在撰写本文时，全球已有超过 500 万人死于 COVID-19，因此研究领导者的反应对于开发控制全球大流行的治疗方法至关重要。随着临床研究领导者紧急将现有的研究计划和资源重新用于 COVID-19 大流行，我们有机会反思在生物医学研究中心（BRC）环境中观察到的实践。BRC 是英格兰领先的 NHS 组织与大学之间的合作伙伴关系，它们为患者利益进行转化研究，由英国国家卫生研究院（NIHR）提供资金。牛津 BRC 支持的研究人员以创纪录的速度迅速建立了许多具有全球影响力的 COVID-19 研究。然而，文献中 BRCS 对 COVID-19 大流行的具体贡献却很少。首先，我们反思了临床研究领导者的战略工作，为促进 COVID-19 研究建立了具有弹性的 NIHR 研究基础设施。其次，我们讨论了牛津 BRC 支持的 COVID-19 快速研究范例如何在组织和个人层面上体现“能力”、“准备就绪”和“能力”，以应对全球大流行。在动荡的环境中进行快速反应研究需要战略组织领导力来创建具有弹性的基础设施和资源。牛津 BRC 的快速研究范例在动态环境中体现了组织和个人层面的能力和能力，以应对 COVID-19 公共卫生挑战。这种反应的基础是牛津 BRC 迅速调整和重新利用现有的研究资源和专业知识，以开展快速研究，解决 COVID-19 的不同方面。
